

DAFTAR PUSTAKA

1. Alexiou, G. A., Markoula, S., Gogou, P. & Kyritsis, A. P. 2011. Genetic and molecular alterations in meningiomas. *Clin Neurol Neurosurg*, 113, 261-7.
2. Antinheimo, J., Sallinen, S. L., Sallinen, P., Haapasalo, H., Helin, H., Horelli-Kuitunen, N., Wessman, M., Sainio, M., Jaaskelainen, J. & Carpen, O. 2000. Genetic aberrations in sporadic and neurofibromatosis 2 (NF2)-associated schwannomas studied by comparative genomic hybridization (CGH). *Acta Neurochir*, 142, 1099-104; discussion 1104-5.
3. Begnami, M. D., Palau, M., Rushing, E. J., Santi, M. & Quezado, M. 2007. Evaluation of NF2 gene deletion in sporadic schwannomas, meningiomas, and ependymomas by chromogenic in situ hybridization. *Hum pathol*, 38, 1345-1350.
4. Benson, V. S., Pirie, K., Green, J., Casabonne, D., Beral, V. & Million Women Study, C. 2008. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. *Br J Cancer*, 99, 185-90.
5. Biassoni, R. and Raso, A., 2016. Quantitative Real-Time PCR: Methods and Protocols, Methods in Molecular Biology. *Humana*. 1160.
6. Cea-Soriano, L., Blenk, T., Wallander, M. A. & Rodriguez, L. A. 2012. Hormonal therapies and meningioma: is there a link? *J Cancer Epidemiol*, 36, 198-205.
7. Choy, W., Kim, W., Nagasawa, D., Stramotas, S., Yew, A., Gopen, Q., Parsa, A. T. & Yang, I. 2011. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. *Neurosurg focus*, 30, E6.
8. Claus, E. B., Black, P. M., Bondy, M. L., Calvocoressi, L., Schildkraut, J. M., Wiemels, J. L. & Wrensch, M. 2007. Exogenous hormone use and meningioma risk: what do we tell our patients? *Cancer*, 110, 471-6.
9. Claus, E. B., Calvocoressi, L., Bondy, M. L., Wrensch, M., Wiemels, J. L. & Schildkraut, J. M. 2013. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. *J Neurosurg*, 118, 649-56.
10. Claus, E. B., Park, P. J., Carroll, R., Chan, J. & Black, P. M. 2008. Specific genes expressed in association with progesterone receptors in meningioma. *Cancer Res*, 68, 314-22.
11. Custer, B., Longstreth, W.T., Phillips, L.E., Koepsell, T.D. and Van Belle, G., 2006. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. *BMC cancer*, 6(1), p.152.
12. Dumanski, J. P., Rouleau, G. A., Nordenskjold, M. & Collins, V. P. 1990. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. *Cancer Res*, 50, 5863-7.
13. Goutagny, S., Yang, H. W., Zucman-Rossi, J., Chan, J., Dreyfuss, J. M., Park, P. J., Black, P. M., Giovannini, M., Carroll, R. S. & Kalamirides, M. 2010. Genomic profiling reveals alternative genetic pathways of meningioma

- malignant progression dependent on the underlying NF2 status. *Clin cancer research*, 16, 4155-4164.
14. Ho, C. Y., Mosier, S., Safneck, J., Salomao, D. R., Miller, N. R., Eberhart, C. G., Gocke, C. D., Batista, D. A. & Rodriguez, F. J. 2015. Genetic Profiling by Single-Nucleotide Polymorphism-Based Array Analysis Defines Three Distinct Subtypes of Orbital Meningioma. *Brain Pathol*, 25, 193-201.
 15. Houshmandi, S. S., Emmett, R. J., Giovannini, M. & Gutmann, D. H. 2009. The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. *Mol Cell Biol*, 29, 1472-86.
 16. Hsu, D. W., Efird, J. T. & Hedley-Whyte, E. T. 1997. Progesterone and estrogen receptors in meningiomas: prognostic considerations. *J Neurosurg*, 86, 113-120.
 17. Joseph, J. T., Lisle, D. K., Jacoby, L. B., Paulus, W., Barone, R., Cohen, M. L., Roggendorf, W. H., Bruner, J. M., Gusella, J. F. & Louis, D. N. 1995. NF2 gene analysis distinguishes hemangiopericytoma from meningioma. *Am J Pathol*, 147, 1450.
 18. Joshi, M. and Deshpande, J.D., 2010. Polymerase chain reaction: methods, principles and application. *Int J Biomed R*, 2 (1), 81-97.
 19. Korhonen, K., Auvinen, A., Lyytinen, H., Ylikorkala, O. & Pukkala, E. 2012. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland. *Am J Epidemiol*, 175, 309-14.
 20. Korhonen, K., Salminen, T., Raitanen, J., Auvinen, A., Isola, J. and Haapasalo, H., 2006. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. *J Neurooncol*, 80(1), pp.1-7.
 21. Kuiper, G.G., Lemmen, J.G., Carlsson, B.O., Corton, J.C., Safe, S.H., Van Der Saag, P.T., Van Der Burg, B. and Gustafsson, J.A., 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β . *J Endocrinol*, 139(10), pp.4252-4263.
 22. Leaes, C. G., Meurer, R. T., Coutinho, L. B., Ferreira, N. P., Pereira-Lima, J. F., et al. (2010), 'Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells', *Neuropathology*, 30 (1), 44-9.
 23. Marosi, C., Hassler, M. & Ssler, K. R. 2003. Guidelines to the treatment of meningioma. *Forum (Genova)*, 13, 76-89.
 24. Marosi, C., Hassler, M., Roessler, K., Reni, M., Sant, M., Mazza, E. & Vecht, C. 2008. Meningioma. *Crit Rev Oncol Hematol*, 67, 153-171.
 25. Mawrin, C. & Perry, A. 2010. Pathological classification and molecular genetics of meningiomas. *J Neurooncol*, 99, 379-391.
 26. Murnyák, B., Bognár, L., Klekner, Á. and Hortobágyi, T., 2015. Epigenetics of meningiomas. *Biomed Res Int*, 15, 6
 27. Pravdenkova, S., Al-Mefty, O., Sawyer, J. & Husain, M. 2006. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. *J Neurosurg*, 105, 163-73.
 28. Ragel, B. T. & Jensen, R. L. 2005. Molecular genetics of meningiomas. *Neurosurg focus*, 19, 1-8.

29. Riemenschneider, M. J., Perry, A. & Reifenberger, G. 2006. Histological classification and molecular genetics of meningiomas. *Lancet Neurol*, 5, 1045-54.
30. Sayagués, J. M., Tabernero, M. D., Maíllo, A., Trelles, O., Espinosa, A. B., Sarasquete, M. E., Merino, M., Rasillo, A., Vera, J. F. & Santos-Briz, A. 2006. Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression. *J Neuropathol Exp Neurol*, 65, 445-454.
31. Scarpin, K. M., Graham, J. D., Mote, P. A., & Clarke, C. L. (2009), 'Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression', *Nucl Recept Signal*, 7, e009.
32. Scoles, D.R., Nguyen, V.D., Qin, Y., Sun, C.X., Morrison, H., Gutmann, D.H. and Pulst, S.M., 2002. Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. *Hum mol genet*, 11(25), pp.3179-3189.
33. Simon, M., Von Deimling, A., Larson, J. J., Wellenreuther, R., Kaskel, P., Waha, A., Warnick, R. E., Tew, J. M. & Menon, A. G. 1995. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. *Cancer res*, 55, 4696-4701.
34. Skiriute, D., Tamasauskas, S., Asmoniene, V., Saferis, V., Skauminas, K., Deltuva, V. & Tamasauskas, A. 2011. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas. *J Neurooncol*, 102, 89-94.
35. Vegeto, E., Shahbaz, M.M., Wen, D.X., Goldman, M.E., O'Malley, B.W. and McDonnell, D.P., 1993. Human progesterone receptor A form is a cell-and promoter-specific repressor of human progesterone receptor B function. *J. Mol. Endocrinol.*, 7(10), pp.1244-1255.
36. Wang, X., Crowe, P.J., Goldstein, D. and Yang, J.L., 2012. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers. *Int J Oncol*, 41(4), pp.1181-1191.
37. Wellenreuther, R., Kraus, J. A., Lenartz, D., Menon, A. G., Schramm, J., Louis, D. N., Ramesh, V., Gusella, J. F., Wiestler, O. D. & Von Deimling, A. 1995. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. *Am J Pathol*, 146, 827-32.
38. Williams, S.P. and Sigler, P.B., 1998. Atomic structure of progesterone complexed with its receptor. *Nature*, 393(6683), p.392.
39. Zang, K. 2001. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. *Cytogenet Genome Res*, 93, 207-220.